There must be measurable disease at study entry\r\n* Note: a measurable node must have an LDi (longest diameter) greater than 1.5 cm; a measurable extranodal lesion should have an LDi greater than 1.0 cm; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)
Subjects must have measurable or evaluable disease:\r\n* Evaluable disease must be evidenced by computed tomography (CT) or positron emission tomography (PET) scans (abnormal PET scans may be used as long as the CT portion is of diagnostic quality)\r\n* Subject must have at least one objective measurable disease parameter:\r\n** Measurable disease on cross sectional imaging that is >= 2 cm in the longest diameter and measurable in 2 perpendicular dimensions\r\n** Splenomegaly > 13 cm in cranio-caudal dimension as measured by CT
Measurable disease sites on CT scan (>1.5 cm in longest dimension)
Measurable disease as defined by IWG for PTCL, i.e., at least 1 measurable disease lesion > 1.5 cm in at least one dimension by 18FDG-PET-CT, MRI, or diagnostic CT
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that is:\r\n* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI) and/or\r\n* A malignant lymph node is considered measurable if its short axis is > 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm)\r\n* Note: tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? 1 lesion that measures > 1.5 cm in the longest dimension and ? 1.0 cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.
Radiographic evidence of measurable disease tumor lesion (? 1cm in greatest dimension) or nodal disease (>1.5cm in greatest dimension)
Subject has measurable disease on cross-sectional imaging by computed tomography (CT) with at least one (post-biopsy) measurable lesion ? 2.0 cm in its longest dimension.
Radiographically measurable disease with a demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extranodal lesion at least 1.0 cm in its largest dimension
For diseases other than Waldenstrom's macroglobulinemia (WM), presence of radiographically measurable presence of ? 1 lesion that measures ? 2.0 cm in the longest dimension (LD) and ? 1.0 cm in the longest perpendicular dimension (LPD)
Measurable disease by tumor imaging with at least one lesion >= 1.5 cm in at least one dimension
Measurable disease that has not been previously irradiated on computed tomography (CT) scans of at least 2 cm, OR if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; imaging must be completed no greater than 6 weeks prior to study enrollment
Participants must have measurable disease, defined as lymphocytosis >= 5,000/ul, or at least one palpable or CT measurable lesion > approximately 1.5 cm, or bone marrow involvement > approximately 30%
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?1 non-biopsied, non-irradiated lesion that measures ?2.0 cm in the longest dimension [LD] and ?1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]).
Have measurable disease (1.5 cm or greater in the longest diameter of nodal or extranodal disease)
Measurable Disease\r\n* Patients must have measurable disease per RECIST 1.1 by computer tomography (CT) scan or magnetic resonance imaging (MRI)\r\n* Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
Measurable disease that can be accurately measured in at least one dimension as >= 2.0 cm with computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) techniques; extranodal disease that is measurable by fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) imaging only will also be allowed; note that if an excisional biopsy was performed that removed the sole site of measurable disease, the patient will not be eligible for leukapheresis and generation of CAR T cell product
Measurable disease: for WM presence of monoclonal IgM immunoglobulin concentration on serum electrophoresis, with lymphoplasmacytic marrow infiltrate; for MZL: measurable nodal disease measuring at least 1.5 cm in longest dimension, or splenomegaly
Have measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease)
All patients should have measurable disease; measurable disease is defined as a lymph node or tumor mass that is >= 1.5 cm in at least one dimension by computed tomography (CT) or the CT portion of the PET/CT
Measurable disease: subjects must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography (spiral CT) or magnetic resonance imaging (MRI)
At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as >= 1.0 cm with computed tomography [CT] scan, CT component of a positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI]) or at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is >= 1.5 cm when assessed by CT scan)\r\n* NOTE: tumor lesions in a previously irradiated area are not considered measurable disease
For diseases other than CLL, LPL, and HCL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >= 1 lesion that measures >= 2.0 cm in the longest dimension [LD] and >= 1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measureable disease will be defined as serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the Second International Workshop on LPL for requiring treatment
Patients should have measurable metastatic disease in the liver, defined (for the purpose of this study) as at least 1 measurable lesion more than 2 cm in size and readily accessible to ultrasound (US) or computed tomography (CT)-guided biopsy
Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size or assessable disease
For subjects with DLBCL, FL, MCL, HL, or CLL/SLL: presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?1 lesion that measures ?2.0 cm in the longest dimension [LD] and ?1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT]).
Disease that is measurable where:\r\n* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)\r\n* A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible
Measurable disease, defined as >= 1.5 cm on imaging assessment
Measurable disease as defined by at least one tumor that is measurable in two dimensions on CT or magnetic resonance imaging (MRI) scan (minimum size 1.0 cm for at least one lesion)
Measurable disease (at least 1 lesion >= 1.5 cm in diameter) as detected by PET/CT
Patients must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than 1.5 cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI), and are not included in any prior field of radiation given to treat B-NHL\r\n* In patients with CLL, circulating lymphocytes >= 5,000 / mm^3\r\n* In patients with WM/LPL, measurable serum monoclonal immunoglobulin M (IgM)
Patients must have primary tumor =< 10 cm as defined by computed tomography (CT) largest axial dimension
Patients must have measurable disease defined as lesions greater than 1.5 cm that can be accurately measured in two dimensions by CT (preferred), or MRI
Must have measurable disease (e.g., a tumor mass > 1 cm)
Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam
In cases of SLL, subjects must have at least one bidimensionally measurable lesion; one of the measurements must be >= 1.5 cm in one dimension
History of uveal melanoma and documented metastatic disease with at least one measurable lesion is required; which is >= 1 cm x 1 cm (on spiral computed tomography [CT] or equivalent)
Measurable disease:\r\n* For nodal or extranodal disease (lymphoma or breast): must have at least 2 lesions that are >= 20 mm (2.0 cm) in the longest diameter by physical exam and/or on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography PET-computed tomography (CT), that are amenable to intralesional injections as determined by interventional radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures)\r\n* For cutaneous lesions (lymphoma or breast): at least two visible, non-infected skin lesions that are greater than 1 cm and are amenable to intralesional injection
Ann-Arbor Stage 2 (non-contiguous), 3, or 4 disease per Lugano Classification Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? 1 lesion that measures ? 1.5 cm in the longest dimension (LD) and ? 1.0 cm in the longest perpendicular dimension (LPD) as assessed by positron emission tomography-computed tomography (PET-CT), computed tomography (CT) or magnetic resonance imaging (MRI)
Measurable disease with a lymph node or tumor mass >1.5 cm in at least one dimension as assessed by computed tomography (CT)
107 Radiographically measurable disease with a clearly demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extranodal lesion at least 1.0 cm in its largest dimension. In the dose exploration phase in case disease is not radiographically measurable PET positivity (ie, Deauville ?4) instead is acceptable.
Measurable disease defined as:\r\n* Computed tomography (CT)/magnetic resonance imaging (MRI)/ or positron emission tomography (PET) scan, with at least one nodal site of disease which is 1.5 cm in longest dimension, and/or spleen > 13 cm in vertical length, and/or diffuse enlargement of liver with or without focal nodules (Lugano 2014); extra nodal sites with biopsy proven abnormal lesions are allowed including skin\r\n* Patients with only bone marrow involvement will be acceptable
Measurable disease by CT or MRI, but with no single lesion measuring more than 10.0 cm
For diseases other than LPL and CLL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >= 1 lesion that measures >= 2.0 cm in the longest dimension [LD] and >= 1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measurable disease will be defined as serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the Second International Workshop on LPL for requiring treatment
Measurable disease is defined as at least one lesion that can be accurately measured with the longest diameter as >= 1.0 cm by computed tomography (CT) scan or >= 1.0 cm with calipers by clinical examination; the exceptions to these criteria are pathologic lymph nodes, which must be >= 1.5 cm in the short axis when assessed by CT scans with slice thickness =< 0.5 cm
Appropriate stage for study entry based on the following diagnostic workup:\r\n* All patients must have computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen is permitted\r\n* Participants must have measurable disease at study entry, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 2 cm with conventional techniques or as > 1 cm with spiral CT scan\r\n* Patient must have 3 or fewer single or multinodular tumors; for patients with a single lesion, lesion must be 15 cm or less in greatest dimension; for patients with two lesions, no lesion may be greater than 10 cm in greatest dimension; for patients with three lesions, no lesion may be greater than 6 cm in greatest dimension; portal vein involvement or thrombosis combined with a single lesion that is >= 4 cm and =< 15 cm in greatest dimension is allowed
Gynecologic cancer cohort only: measureable disease, defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with CT scan or MRI scan; or CT component of a PET/CT; NOTE: Disease that is measurable by physical examination only is not eligible; EXCEPTION: Patients with ovarian, fallopian, or peritoneal cancer without measurable disease are eligible if two pretreatment CA125 values (documented on two occasions taken at least one week apart) are at least twice the upper limit of normal or twice the nadir value if pretreatment CA125 values never normalized.
Measurable disease, defined as one or more of the following:\r\n* Lymphocytosis >= 5000 in peripheral blood\r\n* Measurable lymph nodes > 1.5 cm on palpation and/or computed tomography (CT) scan\r\n* Organomegaly by physical exam and/or CT scan
Measurable disease as defined by the Cheson Response Criteria for Malignant Lymphoma with at least one lesion >= 1.0 cm in longest diameter by computed tomography (CT) scan
Measurable disease\r\n* Mammographic extent of calcifications must be accurately measurable in at least one dimension with each lesion >= 1 cm and =< 7 cm\r\n* DCIS must be visible on MRI based on central review\r\n* Patients with palpable DCIS or adenopathy are not eligible to participate\r\n* Patients with multifocal or bilateral disease are eligible
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of a ?1.5 cm lesion, as measured in the longest dimension by computed tomography [CT] scan).
Must have ? 1 measurable lesion (?2 cm in longest dimension) or ? 1 measurable extranodal lesion (?1 cm in longest dimension) on computed tomography (CT) scan or magnetic resonance imaging (MRI).
Measurable disease on cross section imaging by CT (computed tomography) that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions as defined by IWG (International Working Group) response criteria for NHL (non-Hodgkin Lymphoma).
Subject with lymphoma who has measurable disease (? 2.0 cm in its longest dimension by computed tomography) or chronic lymphocytic leukemia in need of treatment.
At least 1 measurable (? 2 cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI).
Measurable disease on cross section imaging that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions
Have measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease)
Measurable disease sites on CT scan (>1.5 cm in longest dimension)
Measurable disease (at least one lesion that is 1.5 cm in the longest diameter on cross?sectional imaging and measurable in 2 perpendicular dimensions per computed tomography [CT]) for non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) subjects; for myeloma patients measurable disease is defined as presence of more than 5% plasma cells in the bone marrow aspiration and/or presence of monoclonal gammopathy in serum protein electrophoresis (SPEP) and immunofixation
Participants must have measurable disease (lymphocytosis > 5,000/ul, or palpable or CT measurable lymphadenopathy > 1.5 cm, or bone marrow involvement > 30%)
Measurable disease with a lymph node or tumor mass > 1.5 cm in at least one dimension as assessed by computed tomography (CT)
Measurable disease with a lymph node or tumor mass ?1.5 cm in at least one dimension by CT, PET/CT or MRI.
Patients must have measurable disease per RECIST 1.1 by computed tomography (CT) scan or magnetic resonance imaging (MRI); lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes); index lesions for the purpose of RECIST 1.1 measurements will not be selected from within the radiation therapy treatment field; however, if there is evidence of disease progression within the radiation treatment field, measurement of the progressing lesions will be documented
Measurable disease as assessed by 2 dimensional measurement by computed tomography (CT) (> 2 cm or 1.5 cm if 0.5 cm slices are used, as in spiral CT scan)
Patient has measurable disease as defined by a tumor mass > 1.5 cm in one dimension.
Measurable disease defined as: \r\n* At least one non-nodal lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with spiral computed tomography (CT) scan, >= 2 cm with CT component of a positron emission tomography (PET)/CT or magnetic resonance imaging (MRI); and/or\r\n* A lymph node whose short axis must be > 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible
Measurable disease as assessed by 2 dimensional measurements by computed tomography (CT) (>= 1.5 cm)
Measurable disease defined by at least 1 lesion >= 1 cm
Measurable disease with a lymph node or tumor mass >1.5 cm in at least one dimension as assessed by computed tomography (CT)
Must have measurable disease (e.g., a tumor mass > 1 cm)
Measurable disease of at least 1.5 cm
Must have a documented diagnosis of CLL/ SLL requiring treatment (per IWCLL guidelines). In addition: a. Presence of at least one clinically measurable lesion: i. nodal lesion that measures ? 1.5 cm in longest dimension (LD) and ? 1.0 cm in longest perpendicular dimension (LPD), or ii. spleen that measures ? 14 cm in longest vertical dimension (LVD) with a minimum of 2 cm enlargement, or iii. liver that measures ? 20 cm in LVD with a minimum of 2 cm enlargement, or iv. peripheral blood B lymphocyte count > 5000/uL.
Patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least 10 mm on CT imaging)
At least one measurable lesion ? 2 cm in longest diameter by CT and/or MRI scan
At least one measurable lesion that is > 1.5 cm in at least one dimension
?1 measurable lesion site on CT scan (>1.5 cm in longest dimension). Lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by MRI instead. (Subjects with spleen-only disease are considered as not having measurable disease.)
Measurable disease of at least 1.5 cm
Bidimensionally measurable disease with at least 1 lesion >= 2.0 cm in a single dimension
At least one lesion by CT or MRI ? 2 cm
Participants in the Kinetic Studies Arm cannot have non-measurable disease (< 1 cm) by CT
Measurable disease on MRI defined as tumor measuring at least 1 cm in two perpendicular dimensions
Measurable disease (>= 1.5 cm) as assessed by 2 dimensional measurement by computed tomography (CT)
Measurable disease (at least one lesion on radiographic or exam assessment measuring >= 2 cm in longest axis)
For iNHL: measurable nodal disease, defined as the presence of >= 1 nodal lesion that measures >= 2 cm in a single dimension as assessed by computed tomography (CT) or magnetic resonance imaging (MRI)
Criteria 4, Participants have measurable disease which is equal to one or more metastatic liver lesions that can be accurately and serially measured that are greater than or equal to 1 cm dimension and for which the longest diameter is greater or equal to 1 cm as measured by CT (Computed Tomography) scan or magnetic resonance imaging. The metastatic liver lesion(s) must not be in an area that received prior localized therapies.